S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
S&P 500   5,088.80 (+0.03%)
DOW   39,131.53 (+0.16%)
QQQ   436.78 (-0.29%)
AAPL   182.52 (-1.00%)
MSFT   410.34 (-0.32%)
META   484.03 (-0.43%)
GOOGL   143.96 (-0.09%)
AMZN   174.99 (+0.23%)
TSLA   191.97 (-2.76%)
NVDA   788.17 (+0.36%)
NIO   5.40 (-7.69%)
AMD   176.52 (-2.94%)
BABA   75.96 (-0.22%)
T   16.80 (+1.27%)
F   12.15 (+0.25%)
MU   86.00 (+0.10%)
CGC   3.36 (-0.30%)
GE   153.33 (+1.09%)
DIS   107.74 (+0.09%)
AMC   4.43 (+0.23%)
PFE   27.76 (+0.76%)
PYPL   59.16 (+1.39%)
XOM   103.84 (-0.88%)
NASDAQ:IMPL

Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis

Notice: This company has been marked as potentially delisted and may not be actively trading.
Today's Range
N/A
50-Day Range
$0.04
$0.84
52-Week Range
N/A
Volume
720,000 shs
Average Volume
682,655 shs
Market Capitalization
$956,000.00
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

IMPL stock logo

About Impel Pharmaceuticals Stock (NASDAQ:IMPL)

Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.


IMPL Stock News Headlines

This is the #1 Stock to Buy for the AI Tidal Wave
Marc Chaikin warned people about NVDA before its 2023 bull run - now he’s naming his next pick or the AI tidal wave. Learn more here.
Impel Pharmaceuticals (IMPL) Receives a Hold from JonesTrading
1907, 1929, 1998, 2007--and now 2023?
Analyst who called Lehman Bros. collapse says exact same scenario that occurred in 4 of America’s biggest economic calamities is unfolding again now. More here.
Biotech Catches Major Premarket Bid
84P.SG - Impel Pharmaceuticals Inc
Impel Pharmaceuticals Inc. (IMPL)
Impel Pharmaceuticals gets new CFO
See More Headlines
Receive IMPL Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/15/2021
Today
2/23/2024
Next Earnings (Estimated)
3/22/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:IMPL
Fax
N/A
Employees
160
Year Founded
N/A

Profitability

Net Income
$-106,310,000.00
Net Margins
-353.93%
Pretax Margin
-353.93%

Debt

Sales & Book Value

Annual Sales
$20.99 million
Book Value
($1.86) per share

Miscellaneous

Free Float
22,418,000
Market Cap
$956,000.00
Optionable
Not Optionable
Beta
1.17
Metaverse Stocks And Why You Can't Ignore Them Cover

Thinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Key Executives

  • Mr. Leonard S. Paolillo (Age 44)
    Interim President & CEO
    Comp: $523.97k
  • Dr. John D. Hoekman Ph.D. (Age 42)
    Co-Founder and Chief Technology & Development Officer
  • Mr. Michael W. Kalb CPA (Age 52)
    Chief Financial Officer
  • Ms. Jennifer L. Berman
    Vice President of Marketing
  • Ms. Sarah Wille
    Vice President of Human Resources
  • Dr. Lynn C. Gold Ph.D. (Age 66)
    Senior Vice President of Regulatory
  • Mr. Scott Youmans (Age 56)
    Senior Vice President of Technical Operations














IMPL Stock Analysis - Frequently Asked Questions

When is Impel Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, March 22nd 2024.
View our IMPL earnings forecast
.

How were Impel Pharmaceuticals' earnings last quarter?

Impel Pharmaceuticals Inc. (NASDAQ:IMPL) announced its earnings results on Monday, November, 15th. The company reported ($1.24) earnings per share for the quarter, missing the consensus estimate of ($0.82) by $0.42. The firm earned $0.09 million during the quarter.

When did Impel Pharmaceuticals IPO?

(IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow acted as the underwriters for the IPO.

This page (NASDAQ:IMPL) was last updated on 2/23/2024 by MarketBeat.com Staff